In the critical care setting, augmented renal clearance (ARC) is increasingly recognized as one of the leading causes of subtherapeutic antibiotic exposure \[[@CR1]\]. However, commonly used formulas for estimating glomerular filtration rate (GFR) are inaccurate in patients with ARC and the 24-h urinary creatinine clearance (Cr~CL~) remains the best available approach for optimizing empirical antimicrobial therapy \[[@CR2]\]. On the other hand, no study has evaluated the clinical and prognostic value of the kinetic estimated GFR (KeGFR) in this context. We thus aimed to determine whether KeGFR could be a reliable alternative to measured Cr~CL~ in critically ill patients needing early initiation of an appropriate piperacillin dosing regimen.

For this purpose, we retrospectively analyzed 60 consecutive patients who underwent 24-h urinary Cr~CL~ measurements and therapeutic drug monitoring during the first 3 days of antimicrobial therapy of piperacillin administered 16 g/day continuously. The protocol pertaining to this substudy has been published elsewhere \[[@CR3]\]. As previously described, the corresponding KeGFR was calculated as follows: $\documentclass[12pt]{minimal}
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                \begin{document}$$ \frac{\mathrm{Baseline}\ \mathrm{sCr}\ \mathrm{x}\ \mathrm{eGFR}}{\mathrm{Mean}\ \mathrm{sCr}}\times \left(1-\frac{24\ \mathrm{x}\ \Delta \mathrm{sCr}}{\Delta \mathrm{t}\ \mathrm{x}\ \mathrm{Max}\Delta \mathrm{sCr}/\mathrm{Day}}\right) $$\end{document}$ with eGFR derived from the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation using serum creatinine (sCr) before admission, Δt fixed at 24 h between two sCr measurements, and maximal sCr increase per day approximated to 133 μmol/L \[[@CR4]\]. ARC was defined by a measured Cr~CL~ ≥ 130 mL/min/1.73 m^2^. Piperacillin underdosing was arbitrarily defined by a free drug concentration ≤ 32 μg/ml at steady state.

Among the 180 samples analyzed, the incidence of ARC was 48% (median Cr~CL~ values = 124 \[83--170\] ml/min/1.73 m^2^) and the incidence of piperacillin underdosing was 51% (median piperacillin concentrations = 32 \[22--47\] μg/ml). The diagnostic agreement between KeGFR and Cr~CL~ was only moderate (κ = 0.48 \[95% confidence interval 0.4--0.55\]) (Fig. [1](#Fig1){ref-type="fig"}). Comparison between KeGFR and Cr~CL~ showed a mean bias of − 8.7 ml/min/1.73 m^2^ and limit of agreement from − 99 ml/min/1.73 m^2^ to 82 ml/min/1.73 m^2^. Finally, the area under the ROC curve generated for KeGFR was significantly lower than the one generated for measured Cr~CL~ for prediction of piperacillin underdosing (0.76 \[0.68--0.83\] vs 0.85 \[0.79--0.91\], *p* = 0.03; Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Correlation between measured Cr~CL~ and KeGFR (r^2^ = 0.54, *p* \< 0.0001) and repartition of samples with (*white circles*) or without (*black circles*) piperacillin underdosing, defined by an unbound concentration ≤ 32 μg/ml. ARC was defined by a measured Cr~CL~ or a KeGFR ≥ 130 ml/min/1.73 m^2^. Samples in the *gray shaded area* are considered to be well classifiedFig. 2Receiver operating characteristics (ROC) curves evaluating the ability of KeGFR and measured Cr~CL~ to predict piperacillin underdosing. Areas under ROC curves between KeGFR and measured Cr~CL~ were compared using the Handley approach. Piperacillin underdosing was defined by a free drug concentration ≤ 32 μg/ml

In conclusion, KeGFR is not interchangeable with measured Cr~CL~ for prediction of piperacillin underexposure in critically ill patients with ARC. Also, scarce data may suggest a better predictive value of Cockcroft-Gault compared to MDRD (Modification of Diet in Renal Disease Study) or CKD-EPI for identifying patients with ARC \[[@CR5]\]; a measured CL~CR~ should be performed to accurately guide drug dosing. This study emphasizes the need for dosing adjustment and therapeutic drug monitoring in patients with ARC.
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